Spain's Ministry of Health has rejected a joint request from three leading national medical organizations to make effective anti-CGRP migraine medications more accessible to patients across the country.
The Spanish Society of Neurology, the Spanish Association of Migraine and Headache, and the Spanish Headache Foundation sent a formal letter asking health officials to remove restrictive prescription rules. However, the ministry notified neurologists that the current funding criteria will not be changed in the short or medium term.
More than five million people in Spain suffer from migraine, a debilitating neurological condition characterized by severe recurring headaches, light sensitivity, and nausea. Neurology societies worldwide consider anti-CGRP medications to be the safest and most effective preventive treatment currently available.
National Health System prescription restrictions
Six anti-CGRP drugs are currently authorized in Spain, with the first of these innovative treatments having arrived in 2019. These specialized therapies work by targeting calcitonin gene-related peptide, a key protein involved in transmitting migraine pain signals within the nervous system.
Robert Belvís, coordinator of the Headache Study Group at the Spanish Society of Neurology, stated that all six drugs represent a major breakthrough in preventive migraine care. He explained that they are particularly effective for patients who experience a high frequency of attacks or who fail to respond to traditional therapies.
The European Medicines Agency, which evaluates medicinal products for the European Union, authorizes anti-CGRP treatments for patients suffering more than four migraine days per month. In contrast, funding criteria under the Spanish National Health System restrict public reimbursement to patients who experience at least eight migraine days per month and who have already failed three different preventive treatments.
Isabel Colomina, president of the Spanish Association of Migraine and Headache, emphasized that these national funding restrictions severely limit patient access. She stressed that migraine is not simply a routine headache, but a critical issue of brain health and women's health that frequently begins early in life, with two out of three patients developing the condition during childhood.
The Spanish Society of Neurology noted that while restrictive funding rules were understandable when anti-CGRP drugs were first introduced due to a lack of direct comparison studies, they no longer reflect scientific evidence. Recent meta-analyses and comparative clinical trials have confirmed that anti-CGRP therapies provide superior efficacy and safety compared to older preventive options.
In their joint petition, the three organizations asked the Ministry of Health to align Spanish rules with European Medicines Agency standards by permitting prescriptions starting at four migraine days per month without requiring prior failure on three other medications. The ministry subsequently notified the neurology society that it will maintain the restrictive criteria.
The health and social toll of migraine
The decision by health authorities reinforces the frustration felt by migraine sufferers, who routinely experience a lack of understanding from broader society. Many people continue to mischaracterize migraine as an ordinary headache rather than a serious chronic medical condition.
Women are disproportionately affected by the illness, suffering from migraine at three times the rate of men. Additionally, individuals with migraine are up to five times more likely to experience symptoms of depression compared to the general population.
Dr. José Miguel Laínez, director of the Spanish Headache Foundation, highlighted that scientific evidence overwhelmingly supports the superior safety and effectiveness of anti-CGRP drugs. He warned that delaying patient access to these therapies causes serious clinical consequences.
Dr. Laínez explained that time equals pain when managing migraine. Forcing patients to try multiple less effective medications before qualifying for anti-CGRP drugs can subject them to more than a year of avoidable pain, increasing the risk of disease progression, brain sensitization, and a reduced response to future treatments.
Economic impact and healthcare savings
Although anti-CGRP drugs originally carried high initial costs, their current price to the Spanish National Health System is between 100 and 200 euros per month for each patient. Neurologists argue that this cost is entirely manageable when weighed against the severe personal, family, workplace, and social impacts of poorly controlled migraine.
Migraine creates a massive economic burden, costing more than 5,000 euros annually per patient in Spain. Over 65 percent of that financial toll results from lost workplace productivity, alongside other substantial indirect expenses.
Experts estimate that at least one third of Spanish migraine patients, amounting to more than two million people, could benefit from anti-CGRP treatments. Medical specialists emphasize that while wider access might seem more expensive initially, it would lower overall long-term costs by reducing disease-related disability.
Dr. Jesús Porta-Etessam, president of the Spanish Society of Neurology, emphasized that delaying access to the most effective treatments increases patient suffering and reduces healthcare efficiency over time. He noted that migraine remains widely underdiagnosed and undertreated, severely damaging the quality of life of those affected.
Dr. Porta-Etessam added that it is unethical to force patients to wait for their condition to deteriorate before receiving proper therapy. He called on the Ministry of Health to reconsider its stance, maintaining that clinical guidelines must be driven by scientific evidence and the individual needs of patients.
Because migraine currently has no cure, the Spanish Society of Neurology reiterated that therapeutic advances must be made available to those who need them. The organization urged anyone suffering from severe headaches to consult a neurologist, as specialists are best equipped to diagnose and treat the condition.
